AstraZeneca PLC (AZN)vsWaystar Holding Corp. Common Stock (WAY)
AZN
AstraZeneca PLC
$186.68
-0.44%
HEALTHCARE · Cap: $294.17B
WAY
Waystar Holding Corp. Common Stock
$25.27
+0.16%
HEALTHCARE · Cap: $4.88B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 5243% more annual revenue ($58.74B vs $1.10B). AZN leads profitability with a 17.4% profit margin vs 10.2%. AZN trades at a lower P/E of 29.0x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
WAY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$186.68
$27.83 discount
Margin of Safety
+3.5%
Fair Value
$24.59
Current Price
$25.27
$0.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Strong operational efficiency at 23.6%
Revenue surging 24.3% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Distress zone — elevated risk
ROE of 3.2% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : WAY
The strongest argument for WAY centers on Price/Book, Debt/Equity, Operating Margin. Revenue growth of 24.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : WAY
The primary concerns for WAY are Altman Z-Score, Return on Equity, Piotroski F-Score. A P/E of 41.7x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a value stock while WAY is a growth play — different risk/reward profiles.
WAY is growing revenue faster at 24.3% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 51/100), backed by strong 17.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Waystar Holding Corp. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Waystar Holding Corp. The company is headquartered in Lehi, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?